Pasar al contenido principal

PREBIO-TNBC: Marcadores de Presicion para Inmuno-Oncologia en Pacientes con Cáncer de Mama Triple-Negativo

PI22/01496

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ILLES BALEARS
Centro realización FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ILLES BALEARS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer

  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Orozco, Javier I. J|||0000-0003-2585-358X
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Valdez, Betsy
  • Wang, Chuan
  • Mezger, Anja|||0000-0002-7337-9547
  • Choi, Eunkyoung
  • Tran, Yan Zhou
  • Yao, Liqun
  • Bonath, Franziska
  • Olsen, Remi-André
  • Ormestad, Mattias
  • Esteller, M|||0000-0003-4490-6093
  • Lupien, Mathieu|||0000-0003-0929-9478
  • Marzese, Diego|||0000-0002-3258-8852
Objectives: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options. Unlike other breast cancer subtypes, the scarcity of specific therapies and greater frequencies of distant metastases contribute to its aggressiveness. We aimed to find epigenetic changes that aid in the understanding of the dissemination process of these cancers. Data description: Using CRISPR/Cas9, our experimental approach led us to identify and disrupt an insulator element, IE8, whose activity seemed relevant for cell invasion. The experiments were performed in two well-established TNBC cellular models, the MDA-MB-231 and the MDA-MB-436. To gain insights into the underlying molecular mechanisms of TNBC invasion ability, we generated and characterized high-resolution chromatin interaction (Hi-C) and chromatin accessibility (ATAC-seq) maps in both cell models and complemented these datasets with gene expression profiling (RNA-seq) in MDA-MB-231, the cell line that showed more significant changes in chromatin accessibility. Altogether, our data provide a comprehensive resource for understanding the spatial organization of the genome in TNBC cells, which may contribute to accelerating the discovery of TNBC-specific alterations triggering advances for this devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors

  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Orozco, Javier I. J.|||0000-0003-2585-358X
  • Valdez, Betsy
  • Salomon, Matthew P.
  • Matsuba, Chikako
  • Solivellas-Pieras, Maria
  • Bedoya-López, Andrés F.
  • Sesé, Borja
  • Mezger, Anja|||0000-0002-7337-9547
  • Ormestad, Mattias
  • Unzueta, Fernando
  • Strand, Siri Hundtofte
  • Boiko, Alexander D.
  • Hwang, Eun Shelley
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • DiNome, Maggie L.|||0000-0002-1926-292X
  • Esteller, M.|||0000-0003-4490-6093
  • Lupien, Mathieu|||0000-0003-0929-9478
  • Marzese, Diego|||0000-0002-3258-8852
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matrix metalloprotease (MMP) dysregulation impacting tumor invasion, which is the first step of the metastatic process. Methods: We combined RNA expression and chromatin interaction data to identify insulator elements potentially associated with MMP gene expression and invasion. We employed CRISPR/Cas9 to disrupt the CCCTC-Binding Factor (CTCF) binding site on an insulator element downstream of the MMP8 gene (IE8) in two TNBC cellular models. We characterized these models by combining Hi-C, ATAC-seq, and RNA-seq with functional experiments to determine invasive ability. The potential of our findings to predict the progression of ductal carcinoma in situ (DCIS), was tested in data from clinical specimens. Results: We explored the clinical relevance of an insulator element located within the Chr11q22.2 locus, downstream of the MMP8 gene (IE8). This regulatory element resulted in a topologically associating domain (TAD) boundary that isolated nine MMP genes into two anti-correlated expression clusters. This expression pattern was associated with worse relapse-free (HR = 1.57 [1.06 - 2.33]; p = 0.023) and overall (HR = 2.65 [1.31 - 5.37], p = 0.005) survival of TNBC patients. After CRISPR/Cas9-mediated disruption of IE8, cancer cells showed a switch in the MMP expression signature, specifically downregulating the pro-invasive MMP1 gene and upregulating the antitumorigenic MMP8 gene, resulting in reduced invasive ability and collagen degradation. We observed that the MMP expression pattern predicts DCIS that eventually progresses into invasive ductal carcinomas (AUC = 0.77, p < 0.01). Conclusion: Our study demonstrates how the activation of an IE near the MMP8 gene determines the regional transcriptional regulation of MMP genes with opposing functional activity, ultimately influencing the invasive properties of aggressive forms of breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer

  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Orozco, Javier I. J.|||0000-0003-2585-358X
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Baker, Jennifer L.
  • Salomon, Matthew P.
  • Martí, Mercè|||0000-0002-1846-0043
  • DiNome, Maggie L.|||0000-0002-1926-292X
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Marzese, Diego|||0000-0002-3258-8852
Immune checkpoint inhibitors (ICI) improve clinical outcomes in triple-negative breast cancer (TNBC) patients. However, a subset of patients does not respond to treatment. Biomarkers that show ICI predictive potential in other solid tumors, such as levels of PD-L1 and the tumor mutational burden, among others, show a modest predictive performance in patients with TNBC. We built machine learning models based on pre-ICI treatment gene expression profiles to construct gene expression classifiers to identify primary TNBC ICI-responder patients. This study involved 188 ICI-naïve and 721 specimens treated with ICI plus chemotherapy, including TNBC tumors, HR+/HER2- breast tumors, and other solid non-breast tumors. The 37-gene TNBC ICI predictive (TNBC-ICI) classifier performs well in predicting pathological complete response (pCR) to ICI plus chemotherapy on an independent TNBC validation cohort (AUC = 0.86). The TNBC-ICI classifier shows better performance than other molecular signatures, including PD-1 (PDCD1) and PD-L1 (CD274) gene expression (AUC = 0.67). Integrating TNBC-ICI with molecular signatures does not improve the efficiency of the classifier (AUC = 0.75). TNBC-ICI displays a modest accuracy in predicting ICI response in two different cohorts of patients with HR + /HER2- breast cancer (AUC = 0.72 to pembrolizumab and AUC = 0.75 to durvalumab). Evaluation of six cohorts of patients with non-breast solid tumors treated with ICI plus chemotherapy shows overall poor performance (median AUC = 0.67). TNBC-ICI predicts pCR to ICI plus chemotherapy in patients with primary TNBC. The study provides a guide to implementing the TNBC-ICI classifier in clinical studies. Further validations will consolidate a novel predictive panel to improve the treatment decision-making for patients with TNBC. Triple-Negative Breast Cancer (TNBC) is an aggressive type of breast cancer, responsible for a substantial burden of breast cancer-related deaths. In recent years, immunotherapy, a therapy that triggers the patient's immune system to attack the tumor, has arisen as a promising treatment in various cancers, including TNBC. However, a subset of patients with TNBC does not respond to this treatment. Here, we employed advanced computational techniques to predict response to immunotherapy plus chemotherapy in patients with primary TNBC. Our method is more accurate than using other existing markers, such as PD-L1, but is not very accurate in patients with non-TNBC breast cancers or non-breast cancers. This method could potentially be used to better select patients for immunotherapy, upfront, avoiding the side effects and costs of treating patients in which immunotherapy might not work. Ensenyat-Mendez et al. construct a gene expression-based machine learning classifier to predict the response of triple-negative breast cancer to immune checkpoint inhibition combined with chemotherapy. Predictive performance of the 37-gene classifier is better than that of PD-1 or PD-L1.